.gif)
Burcon NutraScience Corporation is pleased to announce that it has been granted a U.S. patent, covering technology for the production of its Peazazz® pea protein: U.S. patent no. 9,635,875, was granted on May 2, 2017. This patent is the first to be granted for Burcon’s pea technology by the United States Patent and Trademark Office and confirms that the Company’s approach is unique, distinct and defensible. Burcon anticipates further positive progress, with its patent filings, in due course.
AstraZeneca and MedImmune, its global biologics research and development arm, announced that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate (AAER) in the overall population of severe, uncontrolled asthma patients, compared with placebo in STRATOS 1, the first of two pivotal Phase III trials.
Torrent Pharma, announced that it has completed the acquisition of Regestrone and Pregachieve brands for India from global Pharma player Novartis AG, Switzerland.
Biocon's Bengaluru plant had inspected by USFDA between March 27 to April 7, 2017 and USFDA issued form no. 483 to Biocon, largest biotechnology company of India. USFDA observed total 8 issues which were shared with the company. Shares of Biocon fell down after this reports circulated in media.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
